Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FW1256 is a phenyl analog. It also a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and causes cell apoptosis. FW1256 shows potent anti-inflammatory effects. It also has the potential for cancer and cardiovascular disease treatment.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,330 | 6-8周 |
产品描述 | FW1256 is a phenyl analog. It also a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-κB activity and causes cell apoptosis. FW1256 shows potent anti-inflammatory effects. It also has the potential for cancer and cardiovascular disease treatment. |
体外活性 | FW1256 (200 μM; 24.5 hours; AW264.7 cells) treatment obviously decreases IL-1β, COX-2, iNOS PROTE, and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages. FW1256 reduces NF-κB activation as evidenced by reduced cytosolic phospho-IκBα levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256. FW1256 concentration-dependently reduces TNF-α (IC50: 61.2 μM), IL-6 (IC50: 11.7 μM), PGE2 (IC50: 25.5 μM) and NO (IC50: 34.6 μM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC50s: 414.9 μM, 300.2 μM, 4 μM and 9.5 μM for TNF-α, IL-6, PGE2 and NO, respectively) [1]. |
体内活性 | Treatment with FW1256 (100 mg/kg; i.p.; male C57BL/6 mice), decreases IL-1β, TNFα, nitrate/nitrite, and PGE2 levels in LPS-treated mice [1]. |
分子量 | 247.25 |
分子式 | C12H10NOPS |
CAS No. | 117089-08-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (1011.12 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.0445 mL | 20.2224 mL | 40.4449 mL | 101.1122 mL |
5 mM | 0.8089 mL | 4.0445 mL | 8.089 mL | 20.2224 mL | |
10 mM | 0.4044 mL | 2.0222 mL | 4.0445 mL | 10.1112 mL | |
20 mM | 0.2022 mL | 1.0111 mL | 2.0222 mL | 5.0556 mL | |
50 mM | 0.0809 mL | 0.4044 mL | 0.8089 mL | 2.0222 mL | |
100 mM | 0.0404 mL | 0.2022 mL | 0.4044 mL | 1.0111 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FW1256 117089-08-4 Others FW 1256 FW-1256 Inhibitor inhibitor inhibit